PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15196735

A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer.

Maarten L P Dirkx·John R van Sörnsen De Koste·Suresh Senan
View original source ↗Export metadata ↓

Abstract

PURPOSE: As local tumour control is poor in stage III non-small cell lung cancer (NSCLC), a radiotherapy planning study was performed to evaluate the potential for treatment acceleration by using a simultaneous integrated boost (SIB) technique in patients who had completed induction chemotherapy. METHODS AND MATERIALS: Co-registered pre- and post-chemotherapy planning CT scans from 10 patients who showed tumour regression after induction chemotherapy were used to compare different treatment schedules: (a) a sequential boost plan delivering, in 2 Gy per fraction, 50 Gy to the pre-chemotherapy tumour volume, followed by a sequential boost of 20 Gy to the post-chemotherapy tumour volume; (b) a SIB technique in which the pre- and post-chemotherapy tumour volumes were treated to different dose levels during each treatment fraction using identical total doses and number of fractions as above; (c) progressively more hypofractionated schedules that delivered the SIB technique in 25 and 20 once-daily fractions; (d) the actual clinical treatment plan in which 70 Gy was delivered to the pre-chemotherapy tumour volume in 35 daily fractions. Differences in the fractionation schemes used for these plans were accounted for by using the normalised total dose (NTD) for comparison, thereby assuming an alpha/beta ratio of 10 Gy for tumour and 3 Gy for normal tissues. The risk of normal tissue toxicity was estimated using the average lung NTD, the lung volume receiving NTD > 20 Gy, the oesophageal volume receiving NTD > 50 Gy, and the length of full circumference irradiated to at least 50 Gy. RESULTS: With respect to the sequential boost technique, the SIB technique improved the sparing of the normal tissues in all patients. In most patients, the SIB plan could also be delivered in 25 fractions without increasing the estimated normal tissue toxicity. With SIB25, the mean lung NTD was reduced from 12.1 to 11.7 Gy, and the fraction of healthy lung tissue receiving NTD > 20 Gy by 2% on average. Although the length and volume of oesophagus irradiated to at least 50 Gy increased for some of the patients, the observed values were less than that was the case for the actual delivered treatment. However, special care should be taken to avoid exceeding the spinal cord tolerance in patients whose tumours are located close to the cord. CONCLUSIONS: A SIB technique that delivers at least 50 Gy to the pre-chemotherapy tumour volume permits accelerated radiotherapy in patients with stage III NSCLC without increasing the expected risks of normal tissue toxicity. By reducing the overall treatment time, the SIB technique may improve local tumour control and survival.

Explore related subjects

Carcinoma, Non-Small-Cell LungDose Fractionation, RadiationHumansImage Processing, Computer-AssistedLung NeoplasmsNeoplasm StagingPatient Care PlanningRadiation InjuriesRisk FactorsSurvival AnalysisTomography, X-Ray ComputedTreatment OutcomeClinical TrialJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Maarten L P Dirkx, John R van Sörnsen De Koste, Suresh Senan. 2004. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer.. https://doi.org/10.1016/j.lungcan.2004.01.003

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Subtype-specific clinical significance of RRM1 and RRM2 expression in non-small cell lung cancer: a TCGA-based analysis.

BACKGROUND: Non-small cell lung cancer (NSCLC), including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), exhibits significant molecular heterogeneity. Ribonucleotide reductase (RNR), composed of RRM1 and RRM2, is essential for DNA synthesis and repair, but its subtype-specific clinical significance in NSCLC remains unclear. OBJECTIVE: To investigate the clinical and prognostic significance of RRM1 and RRM2 expression in NSCLC, with a focus on subtype-specific differences between LUAD and LUSC. METHODS: We analyzed RNA expression and clinical data from 980 NSCLC patients in The Cancer Genome Atlas (TCGA). Associations with clinicopathologic characteristics, overall survival, and oncogenic driver alterations were assessed. RESULTS: In LUAD, high RRM2 expression was significantly associated with advanced pathologic stage (p = 0.004), nodal involvement (p = 0.005), higher T stage (p = 0.030), and gender (p = 0.046). In LUSC, RRM2 was associated with age (p = 0.008), pathologic stage (p = 0.006), and N stage (p = 0.001). RRM1 showed no significant associations with stage-related parameters in either subtype. Correlation analyses revealed modest associations between RRM1 and multiple oncogenic drivers, whereas RRM2 showed stronger subtype-specific correlations, particularly with KRAS/BRAF in LUAD and CDKN2A/SOX2 in LUSC. Kaplan-Meier analysis demonstrated that high expression of both RRM1 and RRM2 was associated with poorer overall survival in LUAD, but not in LUSC. However, neither marker remained significant after adjustment for clinicopathological variables in multivariate analysis. CONCLUSION: RRM2 is associated with tumor progression in both NSCLC subtypes, while the prognostic associations of RRM1 and RRM2 are confined to LUAD. Although neither marker demonstrated independent prognostic significance in multivariate analysis, the findings support subtype-dependent roles of RNR components and highlight the potential biological and therapeutic relevance of nucleotide metabolism pathways in LUAD.

Carcinoma, Non-Small-Cell Lung↗
PubMed2026

Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.

UNLABELLED: EGFR mutations are common oncogenic drivers in non-small cell lung cancer (NSCLC), and approximately half of patients develop brain metastases over the course of their disease. Patients with nonclassic EGFR mutations, such as insertions in exon 20, are a high unmet need with a worse prognosis compared with patients with classic EGFR mutations. Here, we describe the discovery and development of enozertinib (formerly ORIC-114), a highly brain-penetrant, orally bioavailable, irreversible inhibitor that targets EGFR exon 20 mutations with unparalleled kinome selectivity. Preclinical studies revealed strong potency and tumor regressions driven by enozertinib across a broad range of atypical EGFR-mutant models. In a phase I clinical trial of enozertinib in patients with advanced NSCLC bearing atypical mutations in EGFR, a patient harboring an EGFR exon 20 insertion experienced sustained complete response of all systemic and brain metastases. Together, these findings identify enozertinib as a promising investigational inhibitor to address the unmet need for brain-penetrant therapies in NSCLC with EGFR exon 20 insertions or other atypical mutations. SIGNIFICANCE: Preclinical and initial phase I clinical data demonstrate the potency, kinome selectivity, efficacy, and brain penetration of enozertinib in NSCLC with EGFR exon 20 insertions and atypical mutations, warranting further clinical development.

Carcinoma, Non-Small-Cell Lung↗
PubMed2024

Polyol pathway-generated fructose is indispensable for growth and survival of non-small cell lung cancer.

Despite recent treatment advances, non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related deaths worldwide, and therefore it necessitates the exploration of new therapy options. One commonly shared feature of malignant cells is their ability to hijack metabolic pathways to confer survival or proliferation. In this study, we highlight the importance of the polyol pathway (PP) in NSCLC metabolism. This pathway is solely responsible for metabolizing glucose to fructose based on the enzymatic activity of aldose reductase (AKR1B1) and sorbitol dehydrogenase (SORD). Via genetic and pharmacological manipulations, we reveal that PP activity is indispensable for NSCLC growth and survival in vitro and in murine xenograft models. Mechanistically, PP deficiency provokes multifactorial deficits, ranging from energetic breakdown and DNA damage, that ultimately trigger the induction of apoptosis. At the molecular level, this process is driven by pro-apoptotic JNK signaling and concomitant upregulation of the transcription factors c-Jun and ATF3. Moreover, we show that fructose, the PP end-product, as well as other non-glycolytic hexoses confer survival to cancer cells and resistance against chemotherapy via sustained NF-κB activity as well as an oxidative switch in metabolism. Given the detrimental consequence of PP gene targeting on growth and survival, we propose PP pathway interference as a viable therapeutic approach against NSCLC.

Carcinoma, Non-Small-Cell Lung↗